Organisation for Oncology and Translational Research
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Women aged ≥ 18 years;
Histologically and/or cytologically confirmed invasive ductal or lobular breast cancer;
Tumor of 3 cm or greater at time of diagnosis
Measurable primary tumor after neoadjuvant treatment before randomization
No prior chemotherapy for breast cancer;
ECOG performance status ≤1 or Karnofsky performace status ≥ 70%
Adequate liver/renal function
Able to swallow whole tablets.
Able to give written informed consent
Able to follow prescription instructions reasonably well
You may not be if
Male patient
Prior history of other malignancy within 5 years of study entry, aside from contralateral breast carcinoma, appropriately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin
Distant metastasis, including skin involvement beyond the breast area
Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study
Clareo Health | Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy
